| titleOfInvention |
Compound, use of same, pharmaceutical composition, processes to modulate the activity of one or more ptpases or other molecules with phosphotyrosine recognition unit (s) in an individual in need of this control, to isolate a protein, to copulate a fluorescent molecule or radiation to a compound, to detect protein tyrosine phosphatase or other molecules, to quantify the amount of protein tyrosine phosphatase or other molecules, and, to determine the function of a given protein tyrosine phosphatase or protein tyrosine phosphatase group or said molecules . |
| abstract |
"COMPOUND, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, PROCESSES TO MODULATE THE ACTIVITY OF ONE OR MORE PTPASES OR OTHER MOLECULES WITH PHOSPHOTYROSOSINE RECOGNITION UNIT (S) IN AN INDIVIDUAL IN NEED OF THIS CONTROL, TO ISOLATE A PROTEIN, TO PROVIDE A PROTECTED PROTEIN. OR RADIOACTIVE TO A COMPOUND, TO DETECT PROTEIN-TYROSINE PHOSPHATASE OR OTHER MOLECULES, TO QUANTIFY THE AMOUNT OF PROTEIN-TYROSINE PHOSPHATASE OR OTHER MOLECULES, AND TO DETERMINE THE FUNCTION OF A DATA PROTEIN-TINE PROTECTION REFERRED TO MOLECULES ". The present invention provides new compounds, new compositions, processes of their use and processes of their manufacture, where the compounds are pharmacologically usable inhibitors of protein tyrosine phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP -2, PTPa, PTPe, PTPm, PTP d, PTPs, PTPx, PTPb, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR and HePTP. These compounds are indicated for the control or treatment of a wide range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignancies, and type I diabetes and type II diabetes. |